Iowa is currently home to 791 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and West Des Moines. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT05950464
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Endometrial Low Grade Endometrioid Adenocarcinoma, Ovarian Low Grade Endometrioid Adenocarcinoma
Register for Updates
MOnaliZumab in Combination with DurvAlumab (MEDI4736) Plus Platinum-based ChemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
NCT05903092
Recruiting
The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Iowa City, Iowa
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
The Effects of the CF Carrier State on the Kidneys and Pancreas
NCT05474417
Recruiting
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/13/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Pancreatic Disease, Kidney Diseases, Carrier State
Register for Updates
Hazard Anticipation Program for Parents of Teen Drivers
NCT06611241
Recruiting
This study will test an intervention that was developed to improve parents\' driving instruction of teens\' hazard anticipation skills when teens are in the learner phase of licensure. Half of the parents in the study will receive the intervention and half will not. Investigators will then compare driving instructions given by parents in the two groups by recording driving sessions that parents and teens have together in that real world and by recording a drive that parents and t... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
02/12/2025
Locations: University of Iowa, Iowa CIty, Iowa
Conditions: Motor Vehicle Accident, Interaction, Parent-Offspring
Register for Updates
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
NCT05592002
Recruiting
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2025
Locations: University of Iowa Institute for Clinical & Translational Science, Iowa City, Iowa
Conditions: Sleep Apnea, Obstructive
Register for Updates
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222
Recruiting
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Helen G. Nassif Community Cancer Center, Cedar Rapids, Iowa
Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)
NCT05587569
Recruiting
Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
02/11/2025
Locations: Foot and Ankle Center of Iowa, Ankeny, Iowa
Conditions: Metatarsus Adductus, Hallux Valgus
Register for Updates
DIAMOND AF Post-Approval Study
NCT05230524
Recruiting
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Iowa Heart Center (West Des Moines IA), West Des Moines, Iowa
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
NCT05040373
Recruiting
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/11/2025
Locations: Clinical Trial Site, Iowa City, Iowa
Conditions: Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Register for Updates
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
NCT04561518
Recruiting
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Gender:
ALL
Ages:
All
Trial Updated:
02/11/2025
Locations: Clinical Trial Site, Iowa City, Iowa
Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Register for Updates